Chemoselective Installation of Amine Bonds on Proteins through Aza-Michael Ligation

Chemical modification of proteins is essential for a variety of important diagnostic and therapeutic applications. Many strategies developed to date lack chemo- and regioselectivity as well as result in non-native linkages that may suffer from instability in vivo and adversely affect the protein’s structure and function. We describe here the reaction of N-nucleophiles with the amino acid dehydroalanine (Dha) in a protein context. When Dha is chemically installed in proteins, the addition of a wide-range N-nucleophiles enables the rapid formation of amine linkages (secondary and tertiary) in a chemoselective manner under mild, biocompatible conditions. These new linkages are stable at a wide range of pH values (pH 2.8 to 12.8), under reducing conditions (biological thiols such as glutathione) and in human plasma. This method is demonstrated for three proteins and is shown to be fully compatible with disulfide bridges, as evidenced by the selective modification of recombinant albumin that displays 17 structurally relevant disulfides. The practicability and utility of our approach is further demonstrated by the construction of a chemically modified C2A domain of Synaptotagmin-I protein that retains its ability to preferentially bind to apoptotic cells at a level comparable to the native protein. Importantly, the method was useful for building a homogeneous antibody-drug conjugate with a precise drug-to-antibody ratio of 2. The kinase inhibitor crizotinib was directly conjugated to Dha through its piperidine motif, and its antibody-mediated intracellular delivery results in 10-fold improvement of its cancer cell-killing efficacy. The simplicity and exquisite site-selectivity of the aza-Michael ligation described herein allows the construction of stable secondary and tertiary amine-linked protein conjugates without affecting the structure and function of biologically relevant proteins.

[1]  Gonçalo J. L. Bernardes,et al.  Precise Probing of Residue Roles by Post-Translational β,γ-C,N Aza-Michael Mutagenesis in Enzyme Active Sites , 2017, ACS central science.

[2]  Dmitry Soloviev,et al.  Rapid Imaging of Tumor Cell Death In Vivo Using the C2A Domain of Synaptotagmin-I , 2017, The Journal of Nuclear Medicine.

[3]  G. Superti-Furga,et al.  Global survey of the immunomodulatory potential of common drugs , 2017, Nature chemical biology.

[4]  Gonçalo J. L. Bernardes,et al.  Posttranslational mutagenesis: A chemical strategy for exploring protein side-chain diversity , 2016, Science.

[5]  Dieter Söll,et al.  A chemical biology route to site-specific authentic protein modifications , 2016, Science.

[6]  Heather Donaghy,et al.  Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates , 2016, mAbs.

[7]  Antoine Maruani,et al.  Recent advances in the construction of antibody-drug conjugates. , 2016, Nature chemistry.

[8]  Nikolaus Krall,et al.  Site-selective protein-modification chemistry for basic biology and drug development. , 2016, Nature chemistry.

[9]  S. Woutersen,et al.  Guanidinium-Induced Denaturation by Breaking of Salt Bridges. , 2015, Angewandte Chemie.

[10]  K. Johnsson,et al.  Imaging and manipulating proteins in live cells through covalent labeling. , 2015, Nature chemical biology.

[11]  Matthew Welborn,et al.  π-Clamp-mediated cysteine conjugation , 2015, Nature Chemistry.

[12]  P. S. Andersen,et al.  Novel antibody–antibiotic conjugate eliminates intracellular S. aureus , 2015, Nature.

[13]  Troy Moore,et al.  One-step site-specific modification of native proteins with 2-pyridinecarboxyaldehydes. , 2015, Nature chemical biology.

[14]  D. Sleep,et al.  Albumin and its application in drug delivery , 2015, Expert opinion on drug delivery.

[15]  Gonçalo J L Bernardes,et al.  Advances in chemical protein modification. , 2015, Chemical reviews.

[16]  P. Senter,et al.  Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates , 2014, Nature Biotechnology.

[17]  En-Wei Lin,et al.  Therapeutic protein-polymer conjugates: advancing beyond PEGylation. , 2014, Journal of the American Chemical Society.

[18]  Christopher D Spicer,et al.  Selective chemical protein modification , 2014, Nature Communications.

[19]  A. Lawson,et al.  Creation of a gated antibody as a conditionally functional synthetic protein , 2014, Nature Communications.

[20]  Chan Hyuk Kim,et al.  A Genetically Encoded aza-Michael Acceptor for Covalent Cross-Linking of Protein–Receptor Complexes , 2014, Journal of the American Chemical Society.

[21]  R. Chari,et al.  Antibody-drug conjugates: an emerging concept in cancer therapy. , 2014, Angewandte Chemie.

[22]  J. Chin,et al.  Cellular incorporation of unnatural amino acids and bioorthogonal labeling of proteins. , 2014, Chemical reviews.

[23]  Magnar Bjørås,et al.  Extending Serum Half-life of Albumin by Engineering Neonatal Fc Receptor (FcRn) Binding* , 2014, The Journal of Biological Chemistry.

[24]  J. Chin,et al.  Bioorthogonal reactions for labeling proteins. , 2014, ACS chemical biology.

[25]  Peter G Schultz,et al.  A general approach to site-specific antibody drug conjugates , 2014, Proceedings of the National Academy of Sciences.

[26]  K. P. Chooi,et al.  Synthetic Phosphorylation of p38α Recapitulates Protein Kinase Activity , 2014, Journal of the American Chemical Society.

[27]  Jennifer M. Smith,et al.  Range-Separated DFT Functionals are Necessary to Model Thio-Michael Additions. , 2013, Journal of chemical theory and computation.

[28]  A. Nelson,et al.  Structural Insights into the Recovery of Aldolase Activity in N-Acetylneuraminic Acid Lyase by Replacement of the Catalytically Active Lysine with γ-Thialysine by Using a Chemical Mutagenesis Strategy , 2013, Chembiochem : a European journal of chemical biology.

[29]  Felix Kratz,et al.  Clinical impact of serum proteins on drug delivery. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[30]  P. Senter,et al.  The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma , 2012, Nature Biotechnology.

[31]  Jason W. Chin,et al.  Designer proteins: applications of genetic code expansion in cell biology , 2012, Nature Reviews Molecular Cell Biology.

[32]  B. G. Davis,et al.  Conversion of cysteine into dehydroalanine enables access to synthetic histones bearing diverse post-translational modifications. , 2012, Angewandte Chemie.

[33]  N. Stephanopoulos,et al.  Choosing an effective protein bioconjugation strategy. , 2011, Nature chemical biology.

[34]  J. Christensen,et al.  Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). , 2011, Journal of medicinal chemistry.

[35]  S. Gerstberger,et al.  Methods for converting cysteine to dehydroalanine on peptides and proteins , 2011 .

[36]  James A Van Deventer,et al.  Residue-specific incorporation of non-canonical amino acids into proteins: recent developments and applications. , 2010, Current opinion in chemical biology.

[37]  K. Brindle,et al.  Comparison of the C2A domain of synaptotagmin-I and annexin-V as probes for detecting cell death. , 2010, Bioconjugate chemistry.

[38]  Emmanuel Baslé,et al.  Protein chemical modification on endogenous amino acids. , 2010, Chemistry & biology.

[39]  Seamus J. Martin,et al.  Expression, purification and use of recombinant annexin V for the detection of apoptotic cells , 2009, Nature Protocols.

[40]  B. G. Davis,et al.  Chemical modification of proteins at cysteine: opportunities in chemistry and biology. , 2009, Chemistry, an Asian journal.

[41]  Paul Polakis,et al.  Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index , 2008, Nature Biotechnology.

[42]  J. Errey,et al.  Facile conversion of cysteine and alkyl cysteines to dehydroalanine on protein surfaces: versatile and switchable access to functionalized proteins. , 2008, Journal of the American Chemical Society.

[43]  A. Krishnan,et al.  Detection of cell death in tumors by using MR imaging and a gadolinium-based targeted contrast agent. , 2008, Radiology.

[44]  D. Truhlar,et al.  The M06 suite of density functionals for main group thermochemistry, thermochemical kinetics, noncovalent interactions, excited states, and transition elements: two new functionals and systematic testing of four M06-class functionals and 12 other functionals , 2008 .

[45]  J. Andersen,et al.  The conserved histidine 166 residue of the human neonatal Fc receptor heavy chain is critical for the pH‐dependent binding to albumin , 2006, European journal of immunology.

[46]  Peter G. Schultz,et al.  A chemical toolkit for proteins — an expanded genetic code , 2006, Nature Reviews Molecular Cell Biology.

[47]  M. Francis,et al.  Reductive alkylation of proteins using iridium catalyzed transfer hydrogenation. , 2005, Journal of the American Chemical Society.

[48]  P. Sadler,et al.  Role of Tyr84 in controlling the reactivity of Cys34 of human albumin , 2005, The FEBS journal.

[49]  K. S. Lam,et al.  Organic reactions in frozen water: Michael addition of amines and thiols to the dehydroalanine side chain of nocathiacins , 2004 .

[50]  T. Connolly,et al.  Michael addition of amines and thiols to dehydroalanine amides: a remarkable rate acceleration in water. , 2003, The Journal of organic chemistry.

[51]  H. Haas,et al.  The role of histamine and the tuberomamillary nucleus in the nervous system , 2003, Nature Reviews Neuroscience.

[52]  J. Sebastião,et al.  Synthesis of β-substituted alanines via Michael addition of nucleophiles to dehydroalanine derivatives , 2000 .

[53]  U. Schmidt,et al.  Optical inducation during biomimetic formation of cysteine. , 1976, Angewandte Chemie.